Monkeypox B5R
Escherichia Coli.
Sterile Filtered clear solution.
Protein is >95% pure as determined by 10% PAGE (coomassie staining).
Description
The E.Coli derived recombinant B5R protein contains the Envelope Monkeypox immunodominant regions, having an Mw of 32kDa. The Monkeypox protein is fused to a 6xHis tag at C-terminus and purified by proprietary chromatographic technique
Product Specs
Monkeypox virus is a viral zoonotic disease transmitted to humans through contact with infected animals, primarily rodents and primates. Symptoms of monkeypox are similar to smallpox, but milder. The virus responsible for monkeypox is an enveloped double-stranded DNA virus, approximately 190 kb in size, belonging to the Orthopoxvirus genus within the Poxviridae family. There are two main genetic clades of monkeypox: the Central African clade, known for its higher transmissibility, and the West African clade. Transmission occurs through bites from infected animals or direct contact with bodily fluids. The incubation period typically lasts 12 days. Common symptoms include fever, rash, headache, swollen lymph nodes, and muscle pain.
The recombinant B5R protein, derived from E. coli, encompasses the immunodominant regions of the Monkeypox virus envelope protein and has a molecular weight of 32 kDa. It is tagged with a C-terminal 6xHis tag and purified using a proprietary chromatographic method.
A clear, sterile-filtered solution.
The recombinant Monkeypox protein solution is supplied in PBS buffer containing 0.05% sodium nitrate and 25mM potassium carbonate (K2CO3).
Upon receipt, store at -20°C. Repeated freezing and thawing should be avoided.
The purity of the protein is greater than 95% as determined by SDS-PAGE analysis using Coomassie blue staining.
Escherichia Coli.
Product Science Overview
Monkeypox is a zoonotic disease caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. The virus was first discovered in 1958 when outbreaks occurred in monkeys kept for research. The first human case was recorded in 1970 in the Democratic Republic of the Congo (DRC), and since then, the infection has been reported in several African countries .
The monkeypox virus has a complex structure and contains several genes that play crucial roles in its replication and pathogenicity. Among these genes, the B5R gene is of particular interest due to its involvement in the virus’s ability to evade the host immune response and facilitate viral spread.
The B5R gene encodes a protein that is essential for the formation of extracellular enveloped virus (EEV), a form of the virus that is released from infected cells and can spread to other cells. The B5R protein is involved in the wrapping of the virus with an additional membrane, which helps the virus evade the host immune system and enhances its ability to infect other cells .
Recombinant B5R protein refers to the B5R protein that has been produced using recombinant DNA technology. This involves inserting the B5R gene into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities. Recombinant B5R protein is used in various research applications, including the development of vaccines and diagnostic tests.
The B5R protein is a target for vaccine development due to its role in the formation of EEV and its ability to elicit an immune response. Vaccines that include the B5R protein can potentially provide protection against monkeypox by inducing the production of antibodies that neutralize the virus and prevent its spread. Recent studies have shown promising results with recombinant vaccines that use genetically modified vaccinia virus to express monkeypox antigens, including the B5R protein .
